Fulgent GeneticsFLGT -1.58%64 Net Current Asset Value is $12.91 as of Mar. 2026, which is 350% above its 10-year median of 2.87. GuruFocus rates FLGT with a GF Score™ of 64/100 and a GF Value™ of $24.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 87.88% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Fulgent Genetics's net current asset value per share for the quarter that ended in Mar. 2026 was $12.91.
The historical rank and industry rank for Fulgent Genetics's Net Current Asset Value or its related term are showing as below:
FLGT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23 Med: 2.87 Max: 13.17
Current: 1.59
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Fulgent Genetics was 13.17. The lowest was 1.23. And the median was 2.87.
FLGT's Price-to-Net-Current-Asset-Value is ranked better than 87.88% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 4
vs FLGT: 1.59
Fulgent Genetics (NAS:FLGT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Fulgent Genetics Net Current Asset Value Related Terms
Fulgent Genetics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FLGT vs MYGN, CSTL, BDSX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $12.91 mean?
Fulgent Genetics (FLGT) has a Net Current Asset Value of $12.91 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Fulgent Genetics and its competitors. This is 350% above median its historical median of 2.87. Over the past decade, Fulgent Genetics' Net Current Asset Value has ranged from 1.23 to 13.17. According to the industry distribution chart, Fulgent Genetics ranks #12 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 12.1%.
Is Fulgent Genetics' Net Current Asset Value too high?
Fulgent Genetics' current Net Current Asset Value of $12.91 is 350% above median its 10-year median of 2.87. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 13.17. The Medical Diagnostics & Research industry median Net Current Asset Value is 4.00. Fulgent Genetics' value of $12.91 is 222.8% above this industry median. Based on the distribution chart, Fulgent Genetics ranks #12 out of 99 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Net Current Asset Value compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #12 out of 99 companies for Net Current Asset Value. This places Fulgent Genetics in the top 12% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.00. Fulgent Genetics' value of $12.91 is 222.8% above this benchmark. Historically, Fulgent Genetics' own Net Current Asset Value has ranged from 1.23 to 13.17 over the past decade. While the company's 10-year median is 2.87 vs. the industry median of 4.00, Fulgent Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 4.00, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulgent Genetics's current Net Current Asset Value of $12.91 is 222.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Net Current Asset Value is $12.91, which is 350% above median its own 10-year median of 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.11, compared to a current price of $20.55 — trading 14.8% below its estimated fair value. The current Net Current Asset Value is $12.91, which is 350% above median its 10-year median of 2.87 and 222.8% above the Medical Diagnostics & Research industry median of 4.00. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Net Current Asset Value is $12.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $20.55 is trading 14.8% below its estimated GF Value™ of $24.11.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Net Current Asset Value: $12.91 (350% above median its 10-year median of 2.87)
GF Value™: $24.11 vs. price of $20.55 (14.8% below fair value)
Industry Position: 222.8% above the Medical Diagnostics & Research median (#12 of 99)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score
Get the complete analysis for FLGT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
